Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss, Minoxidil, finasteride, and RU58841 as potential treatments for it.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

The conversation discusses the lack of significant advancements in hair loss treatments since the introduction of finasteride 22 years ago, with many expressing frustration over the failure of new projects and skepticism about future developments. Some users mention hair transplants and other potential alternatives like Alfatradiol and Fluridil, but acknowledge finasteride's dominance in the market due to its effectiveness and affordability.

NMN is considered safe to use with dutasteride, and it may help reduce grey hairs. Combining NMN with creatine, whey protein, fish oil, and dutasteride is not seen as excessive.

The user is considering minoxidil, clascoterone, and fluridil for hair loss, avoiding finasteride and RU58841. They are also contemplating a hair transplant and exploring the resilience of transplanted hair without finasteride.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

The user experienced worsening hair density after using finasteride, dutasteride, and RU58841, suspecting RU58841 might be the cause. They are considering stopping RU58841 after a scalp biopsy, while others share mixed experiences with RU58841's effectiveness.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.

Exosomes were used for hair loss treatment, showing results 33 days after the second session. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

Stem cell and exosome injections for hair loss are discussed, with skepticism about their effectiveness and concerns about using non-genetically related stem cells. Dr. Deyarmin's treatments are mentioned, with some users questioning their legitimacy and others expressing curiosity.

This conversation discusses the advancements in treatments for hair loss, including finasteride, dutasteride, minoxidil and new promising treatments such as pyrilutamide and verteporfin. Other treatments discussed were taking minoxidil orally, tretinoin to turn non-responders into responders and microneedling to further boost growth.

Mixing finasteride pills with stemoxydine is not recommended due to potential solubility and safety issues. It's advised to consult a healthcare provider for professionally formulated topical finasteride products.

The conversation humorously discusses using off-label drugs like Minoxidil, finasteride, and RU58841 for hair growth. It jokes about the brain absorbing these treatments for maximum keratin production.

The conversation is about using a trivitamin oil mix (Vitamin E, D3, A, Argan Oil, Sunflower Oil) for hair thinning and whether it is safe to apply it after derma rolling. It is advised to wait 12-24 hours after derma rolling before applying any products to avoid infections or allergic reactions.

Winlevi is being discussed as a potential treatment for hair loss. Users are sharing their experiences with Minoxidil, finasteride, and RU58841.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The conversation humorously discusses the exaggerated effects of taking a 500mg pill of dutasteride, with users joking about extreme side effects like excessive hair growth and loss of sensation. It also mentions personal experiences with finasteride and the potential high bioavailability of dutasteride in liquid form.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

User experienced feminizing side effects from finasteride and tried RU, alfatradiol, and finasteride without success. They are now considering treatments like Stemoxydine, Zix, Minoxidil, Dermarolling, Eucapil, and a hair transplant.

The user has been using 1mg of Finasteride daily and vitamins for a month, noticing hair growth, especially at the temples. They plan to share their two-month progress in the future.